# US 2021/0267976 A1 · Pharmaceutical composition for topical wound treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267976 A1
- Document ID: US20210267976A1
- Status: Published application
- Kind: A1
- Application number: 17/323,752
- Filed: 2021-05-18
- Published: 2021-09-02
- Earliest claimed: 2019-09-06
- Assignees: Consejo Nacional De Investigaciones Cientificas Y Tecnicas; Universidad Nacional De Tucuman; Untech Inc.
- Applicants: Consejo Nacional De Investigaciones Cientificas Y Tecnicas; Universidad Nacional De Tucuman; Untech Inc.
- Inventors: Alberto RAMOS VERNIERI; Maria DE LOS ANGELES LAZARTE; Romina Mabel CHAVEZ JARA; Nicolas Abel CERUSICO
- Web page: https://patentgrep.com/patent/US20210267976A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/515: Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/085: having an ether linkage to aromatic ring nuclear carbon
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 31/717: Celluloses
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12Y 301/21001: Deoxyribonuclease I (3.1.21.1)
- A61K 47/38: Cellulose; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A pharmaceutical composition for topical wound treatment comprising one or more nitrogenous heterocyclic compound of 5 or 6 atoms with imide group; one or more deoxyribonuclease enzyme with activity pH between 4.5 and 6.5; and one or more carboxylic acid; kits and process to obtain this pharmaceutical composition and uses for wounds treatment.

## Claims

### Claim at position 1

1-36. (canceled)

### Claim 37

A pharmaceutical composition for topical wound treatment comprising:
about 0.5 to about 50 mg/ml of a nitrogenous heterocyclic compound of 5 or 6 atoms with imide group;
about 0.5 to about 40 μg/ml of a deoxyribonuclease enzyme with activity pH between 4.5 and 6.5; and
about 1 to about 15 mg/ml of a carboxylic acid.

### Claim 38 (depends on 37)

The pharmaceutical composition according to claim 37, wherein the nitrogenous heterocyclic compound of 5 or 6 atoms with imide group comprises a nitrogenous heterocyclic compound of 5 or 6 atoms with imide group selected from the group consisting of ethosuximide, barbituric acid, phenobarbital, 5,5-diethyl barbituric acid, 5-Ethyl-5-(1-methylbutyl) barbituric acid, pentobarbitone, pentobarbital, Nembutal, 5-Ethyl-5-(1-methylpropyl) barbituric acid, Butobarbital, butisol, 5-Allyl-5-(1-methylbutyl)-barbituric acid, secobarbital, Seconal, Phenytoin, Hydantoin and, and a mixture thereof.

### Claim 39 (depends on 37)

The pharmaceutical composition according to claim 37, wherein the deoxyribonuclease enzyme comprises a deoxyribonuclease enzyme selected from the group consisting of DNase, rh-dornase alfa, bovine pancreatic DNase I, DNase II, prokaryotic DNase II or eukaryotic DNase II, DNase II alfa, DNase II beta, porcine spleen DNase II, and a mixture thereof.

### Claim 40 (depends on 37)

The pharmaceutical composition according to claim 37, wherein the carboxylic acid comprises a carboxylic acid selected from the group consisting of citric acid, lactic acid, acetic acid, formic acid, malic acid, tartaric acid, salicylic acid, oxalic acid, benzoic acid, propionic acid, and a mixture thereof.

### Claim 41 (depends on 37)

The pharmaceutical composition according to claim 37, further comprising one or more tensioactive agent selected from the group consisting of polysorbate 20, polysorbate 80, polysorbate 60, sorbitan triestearate, sorbitan monostearate, octoxynol-9, nonoxynol-9, and a mixture thereof.

### Claim 42 (depends on 41)

The pharmaceutical composition according to claim 41, comprising about 5 mg/ml or less of said tensioactive agents.

### Claim 43 (depends on 37)

The pharmaceutical composition according to claim 37, further comprising one or more complex forming acid selected from the group consisting of ethylene glycol tetra acetic acid, ethylenediaminetetraacetic acid, dimercaptosuccinic acid, 2,3-Dimercapto-1-propanesulfonic acid, lipoic acid (1,2-dithiol-3-valeric acid), oxalic acid, and a mixture thereof.

### Claim 44 (depends on 43)

The pharmaceutical composition according to claim 43, comprising about 1 mg/ml or less of said complex forming acid.

### Claim 45 (depends on 37)

The pharmaceutical composition according to claim 37, further comprising one or more hydrophilic reducing acid selected from the group consisting of uric acid, ascorbic acid, lipoic acid and a mixture thereof.

### Claim 46 (depends on 45)

The pharmaceutical composition according to claim 45, comprising about 3 mg/ml or less of said hydrophilic reducing acid.

### Claim 47 (depends on 37)

The pharmaceutical composition according to claim 37, further comprising one or more gelling agent selected from the group consisting of cellulose, nano-crystalline cellulose, bacterial cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, microcrystalline cellulose, carboxymethyl cellulose, carbopol and mixtures thereof.

### Claim 48 (depends on 47)

The pharmaceutical composition according to claim 47, comprising about 25 mg/ml or less one of said gelling agent.

### Claim 49 (depends on 37)

The pharmaceutical composition according to claim 37, further comprising a solution selected from the group consisting of:
(i) acetic acid 0.2M/sodium acetate 0.2M: Ratio 2.78 to 0.66% (v/v), with a pH of about 4.2 to 4.8;
(ii) acetic acid 0.10 M/sodium acetate 0.01 M: Ratio 1.05 to 10.05% (v/v), with a pH of about 5 to 6;
(iii) monobasic potassium phosphate 0.05M, with a pH of about 4.5;
(iv) monobasic potassium phosphate 0.36 M/disodium phosphate 0.07M: Ratio 4.92 to 0.98% (p/v), with a pH of about 5-7;
(v) monobasic potassium phosphate 0.36 M/disodium phosphate 0.10M: Ratio 4.92 to 1.49% (p/v), with a pH of about 6.0;
(vi) citric acid 0.31 M/disodium phosphate 0.20 M: Ratio 2.99 to 1.42% (p/v), with a pH of about 5.8;
(vii) citric acid 0.10 M/sodium citrate 0.03 M: Ratio 1.92 a 0.77% (p/v), with a pH of about 5 to 8;
(viii) Sorensen's phosphate buffer: sodium monobasic phosphate 0.2M/Disodium phosphate 2.3 M: Ratio 1.2 to 16.33% (p/v), with a pH of about 5 to 8;
(ix) Hank's balanced salt solution (HBSS): sodium chloride 0.14 M (0.800%), potassium chloride 5 mM (0.040%), Calcium chloride 1 mM (0.014%), Magnesium sulphate heptahydrate 0.4 mM (0.010%), Magnesium chloride hexahydrate 0.5 mM (0.010%), Disodium phosphate dihydrate 0.3 mM (0.006%), Potassium monobasic phosphate 0.4 mM (0.006%), Glucose 6 mM (0.100%), Sodium bicarbonate 4 mM (0.035%), with a pH of about 5.7;
(x) 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 1M, with a pH of about 6.5;
(xi) 2-(N-Morpholino) ethanesulfonic acid sodium salt, 4-Morpholineethanesulfonic acid (MES sodium salt) 0.5 M, with a pH of about 5.5 to 6.7;
(xii) N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid sodium salt (BES) 0.5 M with a pH of about 6.0; N-(2-Acetamido)-2-aminoethanesulfonic acid (ACES) 0.5 M, with a pH of about 6.0;
(xiii) 2,2′-[(2-Amino-2-oxoethyl)imino]diacetic acid (ADA) 0.2 M, with a pH of about 6.0;
(xiv) piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) 0.5 M, with a pH of about 6.0 to 6.8;
(xv) 3-Morpholino-2-hydroxypropanesulfonic acid (MOPSO) 0.2 M, with a pH of about 6.0;
(xvi) saline solution (0.9%)/MgCL2 (5 mM) with a pH of about 5.5;
(xvii) 1M NaHCO3 solution; and
(xviii) combinations of each of the foregoing.

### Claim 50 (depends on 37)

The pharmaceutical composition according to claim 37, wherein: the nitrogenous heterocyclic compound of 5 or 6 atoms with imide group comprises ethosuximide; the deoxyribonuclease enzyme with activity pH between 4.5 and 6.5 comprises recombinant human Dornase-Alpha; and the carboxylic acid comprises lactic acid.

### Claim 51 (depends on 50)

The pharmaceutical composition according to claim 50, further comprising:
a hydrophilic reducing acid;
a tensioactive agent;
a complex forming acid;
a gelling agent; and
a solution comprising a saline solution 0.9% and MgCl2 5 mM with a pH of about 5.5.

### Claim 52 (depends on 37)

The pharmaceutical composition according to claim 37, having a pH between 4.5 and 6.8.

### Claim 53 (depends on 37)

The pharmaceutical composition according to claim 37, comprising an aqueous solution of:
from about 0.5 to about 30 mg/ml ethosuximide;
from about 1 to about 4 μg/ml recombinant human Dornase-alpha;
from about 1 to about 9 mg/ml lactic acid,
and wherein the pharmaceutical composition further comprises:
about 2.5 mg/ml or less ascorbic acid;
about 3 mg/ml or less polysorbate-80;
about 0.75 mg/ml or less ethylenediaminetetraacetic acid; and
about 17 mg/ml or less hydroxyethyl cellulose.

### Claim 54 (depends on 37)

The pharmaceutical composition according to claim 37, comprising:
from about 0.5 to about 3 mg/ml ethosuximide;
from about 0.97 to about 3.9 μg/ml recombinant human Dornase-alpha;
from about 1.6 to about 8.7 mg/ml lactic acid,
and wherein the pharmaceutical composition further comprises:
about 2.5 mg/ml or less ascorbic acid;
about 3 mg/ml or less polysorbate-80;
about 0.75 mg/ml or less ethylenediaminetetraacetic acid; and
about 17 mg/ml or less hydroxyethyl cellulose.

### Claim 55

A process for producing a pharmaceutical composition, comprising the steps of:
(a) mixing in a solution a nitrogenous heterocyclic compound of 5 or 6 atoms with imide group and carboxylic acid, thereby forming a mixture;
(b) adding an alkaline solution dropwise to the mixture until the pH of the mixture is between 4.50 and 6.50, thereby forming a pH-adjusted mixture; and
(c) sterilizing the pH-adjusted mixture;
(d) adding a deoxyribonuclease enzyme; and
(e) adding a gelling agent.

### Claim 56 (depends on 55)

The process according to claim 55, further comprising one of the following steps:
(f) adding a tensioactive agent;
(g) adding a hydrophilic reducing acid; and
(h) a combination of one or more of steps (f) and (g).
